-
1
-
-
77955635233
-
Cancer statistics
-
Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
33751057732
-
Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium
-
DOI 10.1016/j.juro.2006.08.004, PII S0022534706019732
-
Shariat SF, Karakiewicz PI, Palapattu GS, et al,. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-22 (Pubitemid 44755069)
-
(2006)
Journal of Urology
, vol.176
, Issue.6
, pp. 2414-2422
-
-
Shariat, S.F.1
Karakiewicz, P.I.2
Palapattu, G.S.3
Lotan, Y.4
Rogers, C.G.5
Amiel, G.E.6
Vazina, A.7
Gupta, A.8
Bastian, P.J.9
Sagalowsky, A.I.10
Schoenberg, M.P.11
Lerner, S.P.12
-
3
-
-
0035254218
-
Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients
-
Stein JP, Lieskovsky G, Cote R, et al,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75 (Pubitemid 32120143)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.3
, pp. 666-675
-
-
Stein, J.P.1
Lieskovsky, G.2
Cote, R.3
Groshen, S.4
Feng, A.-C.5
Boyd, S.6
Skinner, E.7
Bochner, B.8
Thangathurai, D.9
Mikhail, M.10
Raghavan, D.11
Skinner, D.G.12
-
4
-
-
77953850928
-
Considerations on implementing diagnostic markers into clinical decision making in bladder cancer
-
Lotan Y, Shariat SF, Schmitz-Drager BJ, et al,. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. Urol Oncol 2010; 28: 441-8
-
(2010)
Urol Oncol
, vol.28
, pp. 441-448
-
-
Lotan, Y.1
Shariat, S.F.2
Schmitz-Drager, B.J.3
-
5
-
-
57649135074
-
Screening for bladder cancer using urine-based tumor markers
-
Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF,. Screening for bladder cancer using urine-based tumor markers. Minerva Urol Nefrol 2008; 60: 247-53
-
(2008)
Minerva Urol Nefrol
, vol.60
, pp. 247-253
-
-
Svatek, R.S.1
Lotan, Y.2
Karakiewizc, P.I.3
Shariat, S.F.4
-
6
-
-
57649126208
-
Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer
-
Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF,. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol 2008; 60: 217-35
-
(2008)
Minerva Urol Nefrol
, vol.60
, pp. 217-235
-
-
Herman, M.P.1
Svatek, R.S.2
Lotan, Y.3
Karakiewizc, P.I.4
Shariat, S.F.5
-
7
-
-
30944466321
-
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay
-
DOI 10.1001/jama.295.3.299
-
Grossman HB, Soloway M, Messing E, et al,. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295: 299-305 (Pubitemid 43112958)
-
(2006)
Journal of the American Medical Association
, vol.295
, Issue.3
, pp. 299-305
-
-
Barton Grossman, H.1
Soloway, M.2
Messing, E.3
Katz, G.4
Stein, B.5
Kassabian, V.6
Shen, Y.7
-
8
-
-
13844274979
-
Detection of bladder cancer using a point-of-care proteomic assay
-
DOI 10.1001/jama.293.7.810
-
Grossman HB, Messing E, Soloway M, et al,. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293: 810-6 (Pubitemid 40250364)
-
(2005)
Journal of the American Medical Association
, vol.293
, Issue.7
, pp. 810-816
-
-
Grossman, H.B.1
Messing, E.2
Soloway, M.3
Tomera, K.4
Katz, G.5
Berger, Y.6
Shen, Y.7
-
9
-
-
0032964744
-
Urinary nuclear matrix protein 22 (NMP22): A diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder
-
DOI 10.1002/(SICI)1097-0339(199905)20:5<285::AID-DC7>3.0.CO;2-T
-
Hughes JH, Katz RL, Rodriguez-Villanueva J, et al,. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 1999; 20: 285-90 (Pubitemid 29205522)
-
(1999)
Diagnostic Cytopathology
, vol.20
, Issue.5
, pp. 285-290
-
-
Hughes, J.H.1
Katz, R.L.2
Rodriguez-Villanueva, J.3
Kidd, L.4
Dinney, C.5
Grossman, H.B.6
Fritsche Jr., H.A.7
-
10
-
-
38849101720
-
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
-
DOI 10.1111/j.1464-410X.2007.07352.x
-
Hutterer GC, Karakiewicz PI, Zippe C, et al,. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int 2008; 101: 561-5 (Pubitemid 351199283)
-
(2008)
BJU International
, vol.101
, Issue.5
, pp. 561-565
-
-
Hutterer, G.C.1
Karakiewicz, P.I.2
Zippe, C.3
Ludecke, G.4
Boman, H.5
Sanchez-Carbayo, M.6
Casella, R.7
Mian, C.8
Friedrich, M.G.9
Eissa, S.10
Akaza, H.11
Serretta, V.12
Hedelin, H.13
Rupesh, R.14
Miyanaga, N.15
Sagalowsky, A.I.16
Perrotte, P.17
Lotan, Y.18
Marberger, M.J.19
Shariat, S.F.20
more..
-
11
-
-
66149108802
-
Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection
-
Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI,. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int 2009; 103: 1368-74
-
(2009)
BJU Int
, vol.103
, pp. 1368-1374
-
-
Lotan, Y.1
Capitanio, U.2
Shariat, S.F.3
Hutterer, G.C.4
Karakiewicz, P.I.5
-
12
-
-
43049114251
-
Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection
-
DOI 10.1111/j.1464-410X.2008.07473.x
-
Lotan Y, Shariat SF, Group NS,. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008; 101: 1362-7 (Pubitemid 351623980)
-
(2008)
BJU International
, vol.101
, Issue.11
, pp. 1362-1367
-
-
Lotan, Y.1
Shariat, S.F.2
Berger, Y.3
Bock, D.4
Brady, J.5
Collini, M.P.6
Dineen, M.7
Grossman, H.B.8
Kassabian, V.9
Katz, G.10
Maralani, S.11
Messing, E.12
Salup, R.13
Soloway, M.14
Stein, B.15
Tomera, K.16
Treiman, A.17
-
13
-
-
0031054459
-
Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer
-
Miyanaga N, Akaza H, Ishikawa S, et al,. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163-8 (Pubitemid 27101701)
-
(1997)
European Urology
, vol.31
, Issue.2
, pp. 163-168
-
-
Miyanaga, N.1
Akaza, H.2
Ishikawa, S.3
Ohtani, M.4
Noguchi, R.5
Kawai, K.6
Koiso, K.7
Kobayashi, M.8
Koyama, A.9
Takahashi, T.10
-
14
-
-
1242315460
-
Risk Stratification for Bladder Tumor Recurrence, Stage and Grade by Urinary Nuclear Matrix Protein 22 and Cytology
-
DOI 10.1016/j.eururo.2003.10.020
-
Shariat SF, Casella R, Wians FH Jr, et al,. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004; 45: 304-13 (Pubitemid 38221403)
-
(2004)
European Urology
, vol.45
, Issue.3
, pp. 304-313
-
-
Shariat, S.F.1
Casella, R.2
Wians Jr., F.H.3
Ashfaq, R.4
Balko, J.5
Sulser, T.6
Gasser, T.C.7
Sagalowsky, A.I.8
Irani, J.9
-
15
-
-
33746678594
-
Variability in the Performance of Nuclear Matrix Protein 22 for the Detection of Bladder Cancer
-
DOI 10.1016/j.juro.2006.04.017, PII S0022534706010184
-
Shariat SF, Marberger MJ, Lotan Y, et al,. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006; 176: 919-26 (Pubitemid 44160707)
-
(2006)
Journal of Urology
, vol.176
, Issue.3
, pp. 919-926
-
-
Shariat, S.F.1
Marberger, M.J.2
Lotan, Y.3
Sanchez-Carbayo, M.4
Zippe, C.5
Ludecke, G.6
Boman, H.7
Sawczuk, I.8
Friedrich, M.G.9
Casella, R.10
Mian, C.11
Eissa, S.12
Akaza, H.13
Serretta, V.14
Huland, H.15
Hedelin, H.16
Raina, R.17
Miyanaga, N.18
Sagalowsky, A.I.19
Roehrborn, C.G.20
Karakiewicz, P.I.21
more..
-
16
-
-
20244362785
-
Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
-
DOI 10.1097/01.ju.0000154696.48217.75
-
Shariat SF, Zippe C, Ludecke G, et al,. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol 2005; 173: 1518-25 (Pubitemid 40524761)
-
(2005)
Journal of Urology
, vol.173
, Issue.5
, pp. 1518-1525
-
-
Shariat, S.F.1
Zippe, C.2
Lubecke, G.3
Boman, H.4
Sanchez-Carbayo, M.5
Casella, R.6
Mian, C.7
Friedrich, M.G.8
Eissa, S.9
Akaza, H.10
Sawczuk, I.11
Serretta, V.12
Huland, H.13
Hedelin, H.14
Rupesh, R.15
Miyanaga, N.16
Sagalowsky, A.I.17
Wians Jr., F.18
Roehrborn, C.G.19
Lotan, Y.20
Perrotte, P.21
Benayoun, S.22
Marberger, M.J.23
Karakiewicz, P.I.24
more..
-
17
-
-
0031965140
-
Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
-
DOI 10.1016/S0022-5347(01)63930-2
-
Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, et al,. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394-8 (Pubitemid 28049240)
-
(1998)
Journal of Urology
, vol.159
, Issue.2
, pp. 394-398
-
-
Stampfer, D.S.1
Carpinito, G.A.2
Rodriguez-Villanueva, J.3
Willsey, L.W.4
Dinney, C.P.5
Grossman, H.B.6
Fritsche, H.A.7
McDougal, W.S.8
-
18
-
-
77953817519
-
Statistical consideration for clinical biomarker research in bladder cancer
-
Shariat SF, Lotan Y, Vickers A, et al,. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010; 28: 389-400
-
(2010)
Urol Oncol
, vol.28
, pp. 389-400
-
-
Shariat, S.F.1
Lotan, Y.2
Vickers, A.3
-
19
-
-
55049116162
-
Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers
-
Vickers AJ,. Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers. Am Stat 2008; 62: 314-20
-
(2008)
Am Stat
, vol.62
, pp. 314-320
-
-
Vickers, A.J.1
-
20
-
-
33750905259
-
Decision curve analysis: A novel method for evaluating prediction models
-
DOI 10.1177/0272989X06295361
-
Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-74 (Pubitemid 44728772)
-
(2006)
Medical Decision Making
, vol.26
, Issue.6
, pp. 565-574
-
-
Vickers, A.J.1
Elkin, E.B.2
-
21
-
-
0030069896
-
Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
-
DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2- 4
-
Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87 (Pubitemid 26072233)
-
(1996)
Statistics in Medicine
, vol.15
, Issue.4
, pp. 361-387
-
-
Harrell Jr., F.E.1
Lee, K.L.2
Mark, D.B.3
-
22
-
-
0023710206
-
Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach
-
DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45
-
(1988)
Biometrics
, vol.44
, pp. 837-845
-
-
Delong, E.R.1
Delong, D.M.2
Clarke-Pearson, D.L.3
-
23
-
-
67349138615
-
Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker
-
Lotan Y, Elias K, Svatek RS, et al,. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009; 182: 52-7
-
(2009)
J Urol
, vol.182
, pp. 52-57
-
-
Lotan, Y.1
Elias, K.2
Svatek, R.S.3
|